Business Wire (Thu, 23-Apr 4:05 PM ET)
Seeking Alpha News (Wed, 22-Apr 9:27 AM ET)
PRNewswire (Tue, 21-Apr 3:02 PM ET)
Business Wire (Tue, 21-Apr 1:09 PM ET)
Globe Newswire (Tue, 21-Apr 12:38 PM ET)
PRNewswire (Tue, 21-Apr 9:01 AM ET)
PRNewswire (Tue, 21-Apr 7:00 AM ET)
Newsfile (Mon, 20-Apr 10:30 PM ET)
Globe Newswire (Mon, 20-Apr 4:00 PM ET)
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Corcept Therapeutics trades on the NASDAQ stock market under the symbol CORT.
As of April 23, 2026, CORT stock price declined to $45.08 with 836,358 million shares trading.
CORT has a beta of 1.59, meaning it tends to be more sensitive to market movements. CORT has a correlation of 0.06 to the broad based SPY ETF.
CORT has a market cap of $4.84 billion. This is considered a Mid Cap stock.
Last quarter Corcept Therapeutics reported $202 million in Revenue and $.20 earnings per share. This fell short of revenue expectation by $-53 million and missed earnings estimates by -$.11.
In the last 3 years, CORT traded as high as $117.33 and as low as $20.84.
The top ETF exchange traded funds that CORT belongs to (by Net Assets): IJR, VTI, VB, FBT, VBK.
CORT has underperformed the market in the last year with a return of -30.3%, while SPY returned +35.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in CORT shares. However, CORT has outperformed the market in the last 3 month and 2 week periods, returning +9.2% and +7.7%, while SPY returned +3.1% and +4.8%, respectively. This indicates CORT has been having a stronger performance recently.
CORT support price is $45.00 and resistance is $48.14 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CORT shares will trade within this expected range on the day.